Skip to main content

Autoimmune Disease clinical trials at UCLA

6 in progress, 5 open to eligible people

Showing trials for
  • Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

    open to eligible people ages 18 years and up

    A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

    Los Angeles 5368361, California 5332921 and other locations

  • Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

    open to eligible people ages 18 years and up

    Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.

    Los Angeles 5368361, California 5332921 and other locations

  • Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

    open to eligible people ages 18-75

    The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

    Los Angeles 5368361, California 5332921 and other locations

  • Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

    open to eligible people ages 18-70

    The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.

    Los Angeles 5368361, California 5332921 and other locations

  • Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    open to all eligible people

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Los Angeles 5368361, California 5332921 and other locations

  • Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

    Sorry, in progress, not accepting new patients

    The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

    Los Angeles 5368361, California 5332921 and other locations

Our lead scientists for Autoimmune Disease research studies include .

Last updated: